Immunoscape forms scientific advisory board of distinguished immunology experts 29 Jan 2021 / 19:30 H. Pix for representational purpose only.
KUALA LUMPUR: Biotech company, ImmunoScape has announced the formation of its Scientific Advisory Board (SAB) comprising leading scientists in immunology and oncology who will help to guide ImmunoScape’s scientific strategy.
The founding members of the SAB bring substantial scientific insight and expertise to assist the company, which include Evan Newell, Ph.D.; Philip Greenberg, M.D.; Patrick Reeves, Ph.D.; and, Paul Thomas, Ph.D.
“To form this scientific advisory board, we brought together key thought leaders within immunology, across academia and industry alike,” said ImmunoScape Director of Scientific Affairs, Michael Fehlings, Ph.D. in a statement.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Biofidelity appoints Wendy J. Levin MD MS as Chief Medical Officer
Biofidelity LimitedJanuary 28, 2021 GMT
Experienced US-based medical oncologist joins Biofidelity prior to launch of first diagnostic product
US-trained oncologist & hematologist with over 15 years industry experience in translational medicine and drug development
Global clinical lead for the Pfizer SMO Inhibitor,
Daurismo, from pre-IND to FDA approval
Clinical development and medical affairs leadership for multiple publicly-traded and private companies
CAMBRIDGE, United Kingdom, Jan. 28, 2021 (GLOBE NEWSWIRE) Biofidelity Ltd, the cancer diagnostics company, today announces the appointment of Wendy J. Levin MD MS as Chief Medical Officer, based in the US. Following Biofidelity’s recent Series A financing, supported by experienced investors BlueYard Capital, Longwall Ventures and Agilent Technologies, the
A syringe is filled with Moderna s COVID-19 vaccine at University Hospital Magdeburg.
PHOTO: RONNY HARTMANN/AFP/GETTY IMAGES
News from U.S. manufacturer Moderna that its COVID-19 vaccine is still “expected to be protective” against a virus variant first detected in South Africa came as a relief to scientists and the public. But the 25 January announcement included a caveat: Antibodies triggered by the vaccine appear to be a little less potent against the new variant, named B.1.351, than the one the vaccine was developed for. So researchers were perhaps even more relieved to hear the company will start development of booster shots tailored to B.1.351 and other variants.
· Global clinical lead for the Pfizer SMO Inhibitor, Daurismo, from pre-IND to FDA approval · Clinical development and medical affairs leadership for multiple publicly-traded and private companies Cambridge, UK 28 January 2021 - Biofidelity Ltd, the cancer diagnostics company, today announces the appointment of Wendy J. Levin MD MS as Chief Medical Officer, based in the US. Following Biofidelity s recent Series A financing, supported by experienced investors BlueYard Capital, Longwall Ventures and Agilent Technologies, the Company is now focused on expanding its executive team as it works towards launch of the Identi-Lung panel in 2021. Dr. Levin s appointment follows those of former Roche executive Heiner Dreismann as Chairman, Stephen Miller as Chief Commercial Officer and Robert Osborne as Chief Operating Officer.